Page 80 - MEMORIA ANUAL 2019 SEHH-FEHH
P. 80

  Programa EsPañol dE TraTamiEnTos En HEmaTología (PETHEma)
MEMORIA ANUAL 2019
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
12-15, 2019. Clin Lymphoma Myeloma. 2019;19(10 Suppl):E94. Abstract: FP-068. Doi: https://doi.org/10.1016/j.clml.2019.09.153.
• Dávila J, González-Calle V, Puig N, Barez A, Escalante F, López R, Alonso JM, Aguilar C, García-Mateo A, Contreras T, Labrador J, Aguilera C, García de Coca A, Hernán- dez R, Mateos MV, Ocio EM. Recovery of policlonal immunoglobulins as a predic- tor factor of increased progression-free survival and overall survival in patients with multiple myeloma ineligible for ASCT. 17th International Myeloma Workshop. Boston, Sep 12-15, 2019. Clin Lymphoma Myeloma. 2019;19(10 Suppl):E176-E177. Abstract: FP-210. Doi: https://doi.org/10.1016/j.clml.2019.09.295.
• Carrasco-León A, Ezponda T, Meydan C, Vítores Valcárcel L, Ordóñez R, Kulis M, Gara- te L, Miranda E, Segura V, Guruceaga E, Vilas-Zornoza A, Alignani D, Castro-Labrador L, Pascual M, Amundarain A, El Omri A, Taba RY, Calasanz MJ, Planes F, Paiva B, Mason CE, San-Miguel J, Martín-Subero JI, Melnick A, Agirre X, Prosper F. Role of lncRNAs as prog- nostic factor and potential therapeutic target in Multiple Myeloma. 17th International Myeloma Workshop. Boston, Sep 12-15, 2019. Clin Lymphoma Myeloma. 2019;19(10 Suppl):E354-E355. Abstract: SP-301. Doi: https://doi.org/10.1016/j.clml.2019.09.585.
• Puig N, Contreras T, Paiva B, Cedena MT, Pérez JJ, Aires I, Agullo C, Martínez- López J, Rodríguez Otero P, González De La Calle V, González MS, Oriol A, Gutiérrez NC, Ríos R, Rosiñol L, Álvarez MA, Calasanz MJ, Bargay J, González AP, Alegre A, Escalante F, Martínez R, de la Rubia J, Teruel AI, De Arriba F, Palomera L, Hernández MT, López J, Martín J, García Mateo A, Ocio EM, García-Sanz R, Bladé J, Lahuerta JJ, San-Miguel JF, Mateos MV. Heavy and Light Chain Monitoring in High Risk Smol- dering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. 61st Annual Meeting of the ASH. Orlando, Dec 7-10, 2019. Blood. 2019;134(Supple- ment_1):1852. https://doi.org/10.1182/blood-2019-128655.
• Garcés JJ, Bretones G, Burgos L, Valdés-Mas R, Alignani D, Álvarez Puente D, Goi- coechea I, García Álvarez M, Gárate S, Rodríguez I, Calasanz MJ, Rodríguez P, Ríos R, Martínez-López J, Millacoy P, Palomera L, Del Orbe R, Pérez A, Agirre X, Flores- Montero J, Sanoja-Flores L, Orfao A, El Omri H, Prosper F, López-Otin C, San-Miguel J, Paiva B. Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM). 61st Annual Meeting of the ASH. Orlando, Dec 7-10, 2019. Blood. 2019;134(Supplement_1):3064. https://doi.org/10.1182/blood-2019-126527.
80
 
























































































   78   79   80   81   82